The Shwartzman reaction is elicited by two injections of lipopolysaccharide (LPS) in mice. The priming LPS injection is given in the footpad, whereas the lethal LPS challenge is given intravenously 24 h later. The injection of interferon 3, (IFN-'y) or interleukin 12 (IL-12) instead of the LPS priming injection induced the lethal reaction in mice further challenged with LPS. Antibodies against IFN-q/when given together with the priming agent, prevented the lethal reaction in mice primed with either LPS, IL-12, or IFN-3'. Antibodies against IL-12, when given together with the priming agent, prevented the lethal reaction in mice primed with either LPS or IL-12 but not with IFN-% These results strongly suggest that LPS induces the release of IL-12, that IL-12 induces the production of IFN-% and that IFN-7 is the cytokine that primes macrophages and other cell types. Upon LPS challenge, the lethal Shwartzman reaction is induced by a massive production of inflammatory cytokines that act on the target sites already sensitized by IFN-7. If mixtures of TNF and IL-1 or mixtures of TNF and IFN-3' are used to challenge mice previously primed with IFN-7 or ILo12, mortality is induced. In the same conditions, the individual cytokines or a mixture of IL-1 and IFN-3' do not replace the LPS challenge. When the mice are primed with LPS, the combination of TNF, IL-1, and IFN-7 induced only a partial mortality incidence suggesting that the involvement of other LPS-induced factors.
B
acterial LPS is a cell wall component of Gram-negative bacteria that is responsible for most of the toxic manifestations associated with bacterial infections. In mice, a lethal shock syndrome, known as the generalized Shwartzman reaction, can be elicited by two consecutive injections of LPS (for review see 1). A priming dose of LPS, injected intradermall), in the footpad (f.p.)l, is followed after 24 h by an intravenous challenge injection of LPS. After this challenge injection, which is not lethal per se, the mice die within the following 48 h from disseminated intravascular coagulation, vascular occlusion, hemorrhage, perivascular accumulation of leukocytes, and necrosis (2) . This hypersensitivity reaction occurs only if the time interval between these injections is crucially fixed at between 18 and 24 h. There is no response when the intravenous challenge of LPS is given either earlier or later, or when the order of priming and challenge 1 Abbreviations used in thispaper: f.p., footpad; h, human; m, mouse; MIF, macrophage inhibiting factor; R, receptor. injections is reversed. FinaUy, the reaction does not occur if both the LPS injections are intradermal or if the priming dose of LPS exceeds an optimum. The careful dosage and timing of the LPS injections and the need of specific routes of administration indicate that the Shwartzman reaction is elicited by induced endogenous factors acting in a precise time sequence. IFN-'y, TNF, and IL-1 are known to be involved in the pathogenesis of the generalized Shwartzman reaction. IFN-7 seems important during the priming phase (3), whereas TNF and IL-1 are thought to be the lethal effector molecules acting on target sites already sensitized by IFN-% The local injection of LPS presumably induces the release of IFN-% which activates macrophages to produce large amounts of TNF and ILol (4, 5) . In addition, endothelial cells activated by IFN-% TNF, and IL-1, enhance their adherence properties to leukocytes and their capacity to release procoagulant and proinflammatory factors (5) . It is not clear how LPS stimulates the release of IFN-7, since the IFN-"/-producing cells, namely NK and T lymphocytes, are poorly responsive to LPS (6) . Recently, a novel cytokine, IL-12, was characterized (7, Induction of the Generalized Shwartzman Reaction in Mice. The generalized Shwartzman reaction was elicited by two consecutive injections ofS. marcescens LPS (1). The priming injection was given in the f.p. and was followed 24 h later by a challenge LPS injection given intravenously. The optimal doses of LPS were determined for each batch of LPS and ranged between I and 5 #g for the f.p. injection and between 200 and 400 #g for the intravenous injection. When the reaction was elicited with cytokines, the priming injection was given intraperitoneally unless otherwise stated, the challenge injection was given intravenously. In all the experiments described, mAbs were injected intraperitoneally. Each experimental group includes from three to five mice. The occurrence of the generalized Shwartzman reaction was evaluated by mortality scores.
Statistical Analysis. Differences between the treatment groups was evaluated with student's t test.
Results

Induction of the Generalized Shwartzman Reaction in Mice.
Groups of five NMRI mice received two consecutive injections of LPS. The priming injection was given in the f.p. and was followed 24 h later by the intravenous challenge injection. The reaction was lethal only if the mice received both the preparative and the challenge injections (87-100% mortality). A single f.p. or a single intravenous injection was ineffective.
Priming of the Mice~Replacement of LPS with IFN-% The role of IFN-3' in the pathogenesis of the Shwartzman reaction was investigated by replacing the priming LPS f.p. injection by IFN-3' (Table 1 , Fig. 1 ). All the mice primed intraperitoneally with 106 U mlFN-T (83/~g) died after the intravenous injection of LPS given 24 h later. The priming effect was dose dependent. In a representative experiment, 65 and 30% lethality were induced after priming with 10 s U and 104 U mlFN-% respectively (Fig. 1) . The priming effect of mlFN-3, was abrogated by boiling the protein (not shown) and was not due to an intrinsic toxicity of the cytokine (two injections of 106 U at 24-h intervals were ineffective, see Table 4 ). Control animals, primed with hlFN-% all survived the LPS challenge (data not shown). These results show that IFN-y can replace LPS in priming the mice to the Shwartzman reaction.
Priming of the Mice~Replacement of LPS with IL-12. Since IL-12 induces the secretion of IFN-% we assessed the hypothesis that IL-12 can mimic the LPS priming effect. Table  I displays the results of the experiments where either the LPS priming f.p. injection or the LPS intravenous challenge injection were replaced by raiL-12. When mice were primed with 10 ng raiL-12 and challenged 24 h later with LPS, 85% died ( Fig. 1) . This priming effect ofmlL-12 was dose dependent (17 and 0% mortality for 1 and 0.1 ng mlL-12, respectively) and was abrogated by boiling the protein (data not shown). The lethality was not due to an intrinsic toxicity of the cytokine. A single injection of 25 #g mlL-12 or two consecutive injections of raiL-12 with a 24-h time interval were ineffective (see Table 4 ). These results show that miLl2 can replace the LPS priming in the Shwartzman reaction and that mlL-12 is 1,000 times more efficient than mlFN-y in priming mice (Table 1, Fig. 1) .
Antibodies against IFN-T Inhibit the Shwartzman Reaction when the Mice Are Primed with LPS, IFN-% or IL-12.
The roles of IFN-T and IL-12 in the pathogenesis of the Shwartzman's reaction were further investigated using a mAb (XMG1,2) that neutralizes mlFN-T activity (Table 2) . A dose of 10 #g mAb XMG1,2 rescued mice from the shock reaction when given intraperitoneally simultaneously with the priming LPS injection (mortality reduced to 10%). Irrelevant rat IgG, mAb 3/73 anti-human IFN-T or mAb 3'R99 anti-human IFN-TR were not effective ( Table 2) . These results were further confirmed using AN18, another mAb anti-IFN-3/(data not
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The Roles of IL-12, IFN-% and TNF-oe in the Shwartzman Reaction For priming, raiL-12 and mlFN-3, can be injected either intraperitoneally or in the f.p.
shown) or GtL20 a mAb raised against the mlFN-'y ( Table  2 ). The antibodies to IFN-y inhibited more efficiently the lethal reaction than antibodies to IFN-3,R. The dosages giving 50% protection were 1 and 30/zg for XMG-1,2 and AN18, respectively, whereas 200/zg of GR20 were needed to reach the same protection level. This difference can be explained by the need to block all the mlFN-~/receptors which are ubiquitously expressed. When the mice were primed intraperitoneally with 105 U mlFN-3,, 87% of the mice died after the LPS challenge (Fig. 2 ). This lethal reaction was partially inhibited (mortality reduced to 40%) by the injection of 100/zg anti-IFN-"y mAb XMG-1,2 ( Fig. 2 A) . About 5/zg of the same mAb gave a complete inhibition of the lethal reaction developed by mice primed with 10 ng mlL-12 and challenged with LPS. The amount of XMG-1,2 that protects the mice primed with mlFN-3, is 10-20-fold higher than the amount needed to reach the same protection level in mice primed with LPS or miLl2 (Fig. 2 A) . It can be explained by the high dose of mlFN-7 (105 U = 8.3/~g) that has to be used to prime the mice. These results suggest that both the priming effects of LPS and mlL-12 are mediated by mlFN-3'.
Antibodies against IL-12 Inhibit the Schwartzman Reaction when the Mice Are Primed with LPS, IL-I2, but not IFN-% When
given simultaneously with the LPS priming injection, goat anti-mlL-12 inhibited the lethal reaction (Fig. 2 B) . A complete protection from lethality was obtained after intraperitoneal injection of 200 ~g goat anti-mlL-12. This result was confirmed that using mAb 5C3 recognizes the 40-kD chain of the raiL-12 (mortality reduced to 20%), whereas mAb 20C2 raised against hlL-12 was almost ineffective (Table 3) . To confirm that the priming effect of mlL-12 is IFN-'y dependent, we assessed the capacity of anti-IL-12 antibodies to inhibit the lethal reaction when the mice are primed with 909
Ozmen et al. The anti-IFN-3" or anti-IFN-3"R antibodies given intraperitoneaUy together with the LPS f.p. injection (0 h) or with the LPS intravenous injection (24 h ) prevent the lethal reaction. XMG1,2 is a rat anti-mlFN-3' mAb and GR-20 is a rat anti-mlFN-3"R mAb. ")'73 is a mouse anti-hlFN-3, mAb and 3,R99 is a mouse anti-hlFN-3,R mAb. Rat Ig is an irrelevant rat IgG. Fig. 2 B) . The antibodies anti-mlL-12 given intraperitoneally together with the LPS f.p. injection (0 h) prevent the lethal reaction. 5C3 and C15.6.7 are rat anti-mlL-12 mAbs, 20C2 is a mouse anti-human IL-12 mAb. GamlL-12 is a goat anti-mlL-12 polyclonal antibody, mlgG, rat Ig and goat IgG are irrelevant mouse, rat IgG, or goat IgG.
LPS, raiL-12, or mlFN-'y (
respectively. When 1.2 x 105 U (10 #g) mlFN-3/were used to prime mice via the f.p. or intraperitoneally, the mortality induced by the LPS challenge was 60 and 40%, respectively. Since raiL-12 or mIFN-y effnciently primed the mice when given intraperitoneally, these cytokines may play a systemic role in the Shwartzman reaction. We assessed this hypothesis by injecting goat anti-raiL-12 antibodies or anti-IFN-3/mAb XMG 1,2 together with the intravenous LPS challenge. When the XMG1,2 antibody was given simultaneously with the LPS challenge (Fig. 3 A, Table 2 ), a significant protection from lethal shock was still observed (100/zg/mouse reduced the mortality to 23%). In the same conditions, 200/~g of goat anti-mlL-12 antibodies were ineffective (Fig. 3 B , Table  3 ). However, neither mlFN-3' nor raiL-12 could replace the challenge LPS injection of the Shwartzman reaction: the mice that were primed with LPS and challenged intravenously 24 h later with 1@ U mlFN-y or 0.1 #g raiL-12, survived (Table  4) . Since the raiL-12 priming effects are mediated by IFN-% these experiments confirm that mlFN-'y plays a role in the lethal reaction.
Toxicity of TNF-cr, IL-I, and IFN-y Injected Intravenously.
To evaluate the role of IFN-% IL-1, and TNF-ol in the challenge phase of the Shwartzman reaction, the toxicity of the cytokines was assessed after a single intravenous injection. (Table 6 ), 2/zg TNF-o~ together with 104 IL-1 and 105 U IFN-'y were toxic, whereas 2/~g TNF-c~ together with 105 IL-1 and 104 U IFN-3, did not induce lethality. The dosages of cytokines applied to challenge mice in the Shwartzman reaction were chosen according to their lack of toxicity as defined in the Tables 5 and 6 .
Challenge of Mice with Cytokines after Priming with LPS. Mice primed with LPS and challenged intravenously
with either TNF-oe (5/~g), IL-1 (106 U), IL-6 (106 U), or mIFN-3/(106 U) did not die (Table 4) . Neither the coinjection of two cytokines, TNF-o~ and IL-1, TNF-c~ and mIFN-% or IL-1 and mlFN-% could replace the LPS challenge in LPSprimed mice (Fig. 4 A) . The challenges with 2 #g TNF-o~, 104 U IL-1, and 104 U mIFN-3, or with 1 #g TNF-ot, 10 a U IL-1, and 105 U mIFN-'y induced 33% mortality in mice previously primed with LPS. The mortality incidence reached 50% in mice primed with LPS and challenged with 2/~g TNF-oe, 105 U IL-1, and 104 U mlFN-% These experiments show that cytokines can induce the lethal Shwartzman reaction in the LPS primed mice; that at least TNF-oe, IL-1, and mlFN-y can elicit the reaction; and that other factors may be necessary to reach 100% mortality incidence.
Challenge of Mice with Cytokines after Priming with IFN-'y or IL-12.
When mice were primed with 105 U mlFN-~ or with 10 ng mid 12 and challenged with single cytokines such as TNF-c~, IL-1, IL-6, or mlFN-3', no mortality was observed (not shown). Fig. 4 shows that the coinjection of two cytokines, either TNF-cr and mlFN-3' or TNF-oe and IL-1, but not IL-1 and mlFN-3', can elicit the lethal reaction in mice primed with mlFN-y or mlL-12. The highest mortality incidence was obtained when mice primed with cytokines were challenged with TNF-a and IFN-% The intravenous injection of 5 #g TNF-a and 104 U mlFN-3' induced 83 and 100% mortality in mice primed with mlL-12 and mlFN-% respectively. In comparison, the injection of 5 #g TNF-oL and 104 U IL-1 was less efficient and induced 33 and 83% mortality in mice primed with mlL-12 or mlFN-3,, respectively. The injection of 2 #g TNF-ot and 10 s U mlFN-3' was lethal only in mice primed with mlFN-3' (67% mortality), whereas the injection of 2 #g TNF-a and 10 s U IL-1 was not effective whichever the priming cytokine.
When the three cytokines were injected to challenge the mice primed with mlFN-~/or mlL-12, the minimal doses giving high mortality incidence were either 2 #g TNF-cz, 104 U IL-1, and 104 U mlFN-3' or 1 /zg TNF-ot, 104 U IL-1, and 10 s U mlFN-y (100% mortality in mice primed with mlFN-3' and 83-100% in mice primed with raiL-12). The decrease from 104 to 103 U of the IL-1 present in the cytokine mixture injected, reduced drastically the lethality of the reaction (0 and 22% mortality in mice primed with IL-12 and IFN-y, respectively). On the contrary, the mortality rates did not change significantly when the mlFN-3' present in the cytokine combination was reduced from 10 4 to 103 U (76 and 83% mortality in mice primed with IL-12 and IFN-% respectively).
These experiments show that TNF-a when coinjected with IL-1 or mlFN-3' can induce the lethal Shwartzman reaction in the mlL-12 or mlFN-3, primed mice and that TNF-a is essential for the lethality of the reaction, whereas IL-1 or mlFN-3' potentiate the TNF-cr effects. Finally, these experiments show that both mlL-12 and mlFN-3/are more efficient priming agents than LPS in the lethal Shwartzman reaction. The results from two individual experiments are expressed in percent of mortality. In each experiment, each treatment group includes three to five mice. * Not tested.
The results from two to six individual experiments are expressed in percent of mortality. In each experiment, each treatment group includes three to five mice. * Not tested.
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The Roles of IL-12, IFN-"/, and TNF-c~ in the Shwartzman Reaction Tables 4 and 5 . Data are pooled from three to five independent experiments with three mice per treatment group. Results are expressed in percentage of mortality.
Discussion
IFN-% TNF, and IL-1 are involved in the generalized Shwartzman reaction elicited in mice. IFN-3, is the main factor during the priming phase while TNF and IL-1 are the lethal effector molecules induced by the LPS challenge (for review, see 1). The anti-IFN-3~ mAbs inhibited the f.p. swelling in mice injected locally with LPS (3) and protected the mice from the lethal reaction (1) . Since the monocytes and macrophages appear to be the principal cells involved in mediating the effects of endotoxin (27, 28) , it is not clear how LPS can stimulate T and NK cells to release IFN-% One hypothesis is that LPS-stimulated macrophages produce IL-1 and IL-6, which in turn activate T cells to release IFN-3, (29) . The relatively low incidence of lethality observed in mice primed with these cytokines and challenged with LPS, suggests that IL-1 and IL-6 are cofactors rather than triggering agents in the priming of mice (data not shown).
913
Ozmen et al.
Recent data showed that LPS can activate macrophages to release IL-12, a cytokine that stimulates T and NK cells to release IFN-~/(9). This finding supports the idea that IL-12 may be the missing link between LPS and IFN-3' in the generalized Shwartzman reaction. Following the same approach as that used for IFN-% we conclude that IL-12 and IFN-3, are both involved in the priming phase of generalized Schwartzman reaction. The experiments with anti-IFN-3~ and anti-IL-12 antibodies show that the priming effect of IL-12 is mediated by IFN-% IL-12 does not contribute to the lethality of the generalized Shwartzman reaction. The anti-IL-12 antibodies injected together with the intravenous LPS challenge do not rescue the primed animals and IL-12 does not replace the LPS challenge. On the contrary, the LPS primed mice treated with anti-IFN-3/antibodies at the time of the LPS challenge surfive. However, IFN-3' does not elicit the lethal reaction when injected instead of the LPS challenge. The protective effect of the anti-IFN-3, antibodies is 10 times less effective than that observed when the same mAbs are given together with the LPS priming. These results show for the first time that IFN-3' contributes to the lethality of the shock reaction but is not a lethal effector molecule. Although evidence points to TNF and IL-1 as the key cytokines leading to the hemodynamic and histologic events of the septic shock (30-33), we never observed a lethal reaction on challenging the mice with either TNF-cr (5 #g) or 106 U IL-1 (3.3 #g) after the LPS priming. The injection of TNF-c~, IL-1, and IFN-3' mixture can induce an intermediate lethality (33%) in the mice primed with LPS. The coinjection of TNF-ol and IL-1 or TNF-ol and IFN-3~ induces a lethal reaction in mice primed with either IL-12 or IFN-% In these conditions, IL-1 and IFN-3' are not lethal. This confirms TNF-oe as the main effector of the Shwartzman reaction but that lethality arises in the presence of either IL-1 or IFN-% These observations suggest that the f.p. priming injection of LPS induces not only IL-12 and IFN-3' but also antiinflammatory factors. The fact that the priming with high dose of LPS, i.e., 10 #g/mouse, inhibits the lethality induced by the LPS challenge supports this hypothesis (1) .
LPS activates many cell types to produce antiinflammatory factors. LPS-activated PMN release enzymes, radicals, and a bactericidal protein called BPI (bactericidal/permeabilityincreasing protein) (34) . This protein competes with lipopolysaccharide binding protein (35) or soluble CD14 and neutralizes LPS so that it cannot activate monocyte/macrophages or injure endothelial cells (36, 37) . Upon LPS activation, monocytes produce not only IL-12, TNF-oe, and IL-1 but also IL-1 receptor antagonist (IL-lra), IL-lra, IL-6 and IL-10 (38-40). Both IL-6 and IL-lra can also antagonize the production and/or the activity of IL-1 (38, 41) . IL-IO inhibits the production of IFN-3', the proliferation of Thl cells (42) and downregulates several macrophage functions, including the secretion of IL-1, IL-6, IL-8, IL-IO, IL-12, and TNF-ol, respiratory burst and MHC class II expression (43, 44) . Since the maximal production of IL-10 occurs 24-48 h after LPS activation of macrophages, its putative inhibitory effect in the Shwartzman reaction would coincide with the challenging phase. Thus, IL-10 could interfere with the activity of the lethal effector cytokines. Recently, Bernhagen (45) reported that the in vivo injection of LPS induces the release of macrophage inhibiting factor (MIF) by pituitary cells. This cytokine is involved in the septic shock but its role is not clear. Hypophysectomised mice are more sensitive to endotoxin, whereas the coinjection of MIF and LPS enhances lethality. Since IL-12 and IFN-'y do not induce MIF and IL-6, such a negative regulatory pathway should not take place in mice primed by IL-12 or IFN-% Recent reports suggest that IL-12 and IFN-3, have opposite effects on IL-10 production. IFN-3, inhibits IL-10 production by monocytes (46) , whereas increased IL-10 production was observed in mice after daily injection of IL-12 for 4-5 d (47), when its relevance for the onset of the shock reaction is questionable.
In conclusion, our data suggest that a cascade of cytokines induces the generalized Shwartzman reaction. The priming f.p. injection of LPS stimulates the release of IL-12 by the macrophages of the draining lymph nodes and activates the production of IFN-3' by T and/or NK cells. IFN-3/promotes the inflammatory functions of macrophage-like and endothelial cells, and sensitizes them to environmental stimuli. Upon the systemic injection of LPS, all the sensitized cells produce 1TNF and IL-1, that together with the newly synthesized IFN-'y, enhance the adherence, and trigger the procoagulant and proinflammatory activities of these cells. Besides IL-1, IFN-3' seems necessary for the manifestation of the TNF lethality in the generalized Shwartzman reaction.
